18 results
8-K
EX-99.1
NDRA
ENDRA Life Sciences Inc
20 May 24
ENDRA Provides Update Following In-person Meeting with FDA
8:05am
to the FDA as a next step prior to initiating the study.
"ENDRA's new regulatory approach is focused on close engagement with the FDA to ensure
8-K
EX-1.1
0xvnrk8usx59a8uqr
18 Dec 20
ENDRA Life Sciences Announces Proposed Public Offering of Common Stock
5:04pm
8-K
EX-1.1
hfl 274y6
27 Mar 20
Entry into a Material Definitive Agreement
5:19pm
8-K
EX-10.2
i69uvynd589mf98nrgo
27 Dec 19
Departure of Directors or Certain Officers
4:06pm
8-K
EX-10.1
mmv9r hw3cv4i81kxn
27 Dec 19
Departure of Directors or Certain Officers
4:06pm
8-K
EX-1.1
k6jw18t
13 Nov 18
ENDRA Life Sciences Announces Proposed Public Offering of Common Stock
12:00am
8-K
EX-1.1
ni7 nz3s27au
16 Oct 18
ENDRA Life Sciences Inc. Announces Proposed Public Offering of Common Stock
4:05pm
- Prev
- 1
- Next